Corporate Overview

Headquartered in Austin, Texas, Mati Therapeutics is developing a non-invasive sustained drug delivery platform to treat ocular diseases, in particular glaucoma.

Four of the founders of Mati previously worked together at QLT Inc., a publicly traded Vancouver-based biotech company focused on ocular diseases and the company responsible for developing Visudyne®, the first medical treatment for age related macular degeneration.